The Value of Stillness
Health Care: Health Services
BG Medicine Inc. (BGMD: NASDAQ)
$1.45 -0.12 | -7.64%
06/18/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -23.77M | -17.58M | -17.16M | -16.14M |
| Operating Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -280.00K | 671.00K | -508.00K | -278.00K |
| (Increase) Decrease in Inventories | -235.00K | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | -565.00K | 0.00 | 2.91M |
| (Decrease) Increase In Payables | 802.00K | 542.00K | 462.00K | -996.00K |
| (Decrease) Increase In Other Current Liabilities | 0.00 | -153.00K | 836.00K | -6.58M |
| (Increase) Decrease In Other Working Capital | -782.00K | 0.00 | 0.00 | -110.00K |
| Other Non-Cash Items | 2.55M | 2.00M | 4.58M | 2.45M |
| Net Cash From Continuing Operations | -21.33M | -14.97M | -11.42M | -17.98M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -21.33M | -14.97M | -11.42M | -17.98M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -85.00K | -93.00K | -77.00K | -697.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -85.00K | -93.00K | 1.98M | 7.51M |
| Issuance of Debt | 10.00M | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 543.00K | 37.88M | 43.00K | 20.00K |
| Repayment of Long-Term Debt | 0.00 | -100.00K | -1.20M | -1.26M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | -213.00K | -1.28M | 4.68M | 0.00 |
| Net Cash From Financing Activities | 10.33M | 36.51M | 3.52M | -1.24M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -11.09M | 21.45M | -5.92M | -11.71M |
Portfolios with BGMD
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks With Big Insider Buy...
- ContributorUnder-$10 Setting Up To Tra...
- Contributor8 Health Care Stocks With R...
Latest BGMD Headlines from TheStreet
- BG Medicine Welcomes Inclusion Of Galectin-3 As Biomarker Of Myocardial Fibrosis In 2013 ACCF/AHA Guideline For Management Of Heart Failure 06.12.13 | 08:06 am
- BG Medicine Announces Late-Breaker Oral Presentation Of New Data On The BGM Galectin-3(R) Test In Heart Failure 05.28.13 | 08:05 am
- 8 Stocks Under $10 Trending Sharply Higher 05.14.13 | 11:05 pm
- BG Medicine, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 05.10.13 | 05:05 pm
- BG Medicine Appoints Dr. Paul Sohmer As Chief Executive Officer 05.09.13 | 07:05 am
- BG Medicine Reports 2013 First Quarter Financial Results 05.09.13 | 07:05 am
- Trenton Health Team Adopts Novel Diagnostic Tool, BGM Galectin-3(R) Test, To Reduce Hospital Readmissions 05.08.13 | 07:05 am
- BG Medicine To Announce First Quarter 2013 Financial Results And Host Conference Call On Thursday, May 9, 2013 05.02.13 | 08:05 am
- BG Medicine Welcomes CE Mark For Galectin-3 Test 04.10.13 | 08:04 am
- BG Medicine Reports Fourth Quarter And Full Year 2012 Financial Results And Provides 2013 Outlook 03.13.13 | 07:03 am
Press Releases for BGMD
- Abbott's Galectin-3 Test Provides Doctors In Europe With New Tool For Assessing The Prognosis Of Chronic Heart Failure Patients - PR Newswire 04.10.13 | 08:04 am
- Health Diagnostic Laboratory, Inc. (HDL, Inc.) Announces Availability Of Galectin-3 Testing Service In Partnership With BG Medicine - PR Newswire 03.24.11 | 08:03 am
- BG Medicine Announces Exercise Of Underwriters’ Over-Allotment Option And Closing Of Initial Public Offering - Business Wire 02.09.11 | 04:02 pm
- BG Medicine Announces Pricing Of Initial Public Offering - Business Wire 02.04.11 | 08:02 am
Partner Headlines for BGMD
- Pre-Market Most Active for Dec 12, 2012 : TLAB, QQQ, NRF, STM, BAC, NOK, LLY, AIG, SIRI, BGMD, FB, AAPL - NASDAQ 12.12.12 | 01:12 pm
- 4 Undervalued And Technically Oversold Healthcare Penny Stocks Poised To Bounce - Seeking Alpha 11.20.12 | 09:11 am
- UPDATE: Ladenburg Thalmann Raises PT to $16.50 on BG Medicine - Benzinga 02.14.12 | 01:02 pm
- Market Update - Benzinga 01.09.12 | 09:01 am
